Feb
22
2022
On demand

Manufacturing of RCA-free adenoviral vectors

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Adenoviral vectors are frequently used as delivery tools for vaccines and gene therapy applications. In most cases, replication-incompetent adenoviruses (RCA) are employed, which, once they have infected a target cell, cannot spread further in a patient‘s body. In such applications, regulatory guidelines require that the formation of RCA during the production process must be minimized. Since the risk of RCA occurrence depends on the adenoviral vector and the cell line used for virus stock generation and manufacturing, the choice of an appropriate cell line and production platform is a critical decision. Ideally, it should allow, among other things, simple, scalable and GMP-compliant production of adenoviral vectors at high titers and without the risk of RCA formation.

Here we present the CAP® Ad platform, a production platform for adenoviral vectors based on CAP® cells and specifically designed to address these requirements. CAP® cells can be cultivated in all common bioreactors using serum-free, chemically defined media. They grow to high densities as single cells in suspension and support high titer, RCA-free adenoviral vector production. The webinar will provide further background information on the CAP® Ad production platform and typical process flows used for adenoviral vector manufacturing at industrial scale.

  • Impact of the adenovirus biology on its use as a viral vector
  • Uses of adenoviral vectors for various medical applications
  • Importance of avoiding RCA in the manufacturing process
  • Achieving industrial scale adenoviral vector production using the CAP® Ad platform

Dr. Nico Scheer

Senior Consultant, Business Development, CEVEC Pharmaceuticals / Professor "Molecular Biology“, FH Aachen University of Applied Sciences

Dr. Nico Scheer has >20 years of experience in research and business development in the life science industry as well as a strong scientific background in molecular biology, immunology and viral vector technologies. He published several peer reviewed scientific articles and book chapters in different fields of research. Dr. Scheer holds a professorship in Molecular Biology at FH Aachen University of Applied Sciences and supports CEVEC Pharmaceuticals GmbH as Senior Consultant Business Development.

SPEAKERS

Nico Scheer
Senior Consultant Business Development at CEVEC Pharmaceuticals GmbH

You might also like

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
28
Days
14
Hrs
9
Min
Register

Optimizing mRNA purification conditions by using a Design of Experiments...

J England
Jenny England
Jenny England
Application Scientist and Innovation Leader at Thermo Fisher Scientific
14 Jun 2022
27
Days
6
Hrs
9
Min
Register

Taking a right first-time approach to optimize end-to-end viral vector...

H Lesch
J Depollier
Hanna Lesch
Hanna Lesch
Chief Technology Officer at Exothera
Julien Depollier
Julien Depollier
Business Director, Americas at Polyplus-transfection
9 Jun 2022
22
Days
6
Hrs
9
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
20
Days
6
Hrs
9
Min
Register

Optimizing E. Coli cell growth performance with in-line, real-time OD600...

T Buch
R Shanbaky
Tanja Buch
Tanja Buch
Technical Director at Biifactory Competence Center
Ramsey  Shanbaky
Ramsey Shanbaky
Bioprocess Applications Manger at C Technologies, Inc - a Repligen Company
1 Jun 2022
13
Days
14
Hrs
9
Min
Register